Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Arvinas, Inc. ARVN

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.27
Total sells
1.42
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — 1 — — — — — —
Sell — 1 — — 9 1 — 6 2 — — —
Insider Ownership
9.57%

Capital & Financial Ratios

Market Cap
543.36
Revenue
316.70
Net Income
9.30
Free Cash Flow
(208.80)
Net Debt
(567.60)
Current Ratio
7.91
Debt/Equity
0.00
P/E ratio
63.77
P/S ratio
1.70
P/B ratio
0.96
Past 5Y EPS Growth
(5.32%)
This Y EPS Growth
96.43%
Next Y EPS Growth
(8,053.92%)
Next 5Y EPS Growth
(23.43%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1,266.50 1,039.40 685.40 567.90
Receivables 7.20 13.70 6.40 54.30
Inventory — — — —
Other — — — —
1,280.20 1,067.30 700.70 652.20
2023 2024 2025 Q'26
Payables 92.20 71.80 69.50 52.20
ST’ Debt — — — —
Other — — — 28.40
257.10 229.80 142.50 82.50
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 15.60 249.70 — —
—
’25 188.80 22.40 41.90 9.50
262.60
’24 25.30 76.50 102.40 59.20
263.40
’23 32.50 54.50 34.60 (43.10)
78.50
’22 26.50 33.80 33.20 37.90
131.40
’21 5.50 5.50 9.30 33.30
53.60
’20 6.24 5.75 7.60 6.32
25.90
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (69.20) (48.30) — —
—
’25 (88.90) (95.40) (59.10) (30.40)
(273.80)
’24 (97.50) 50.30 (128.00) (84.10)
(259.30)
’23 (91.20) (88.70) (84.80) (83.10)
(347.80)
’22 (57.10) (78.60) (66.60) (71.20)
(273.50)
’21 (39.00) (47.40) 681.50 (35.70)
559.40
’20 (16.95) (21.40) (22.38) (28.96)
(89.70)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (70.50) (48.50) — —
—
’25 (89.30) (96.60) (59.20) (30.60)
(275.70)
’24 (97.60) 49.70 (128.70) (84.40)
(261.00)
’23 (92.30) (89.30) (85.90) (83.20)
(350.70)
’22 (59.20) (80.00) (68.80) (72.30)
(280.30)
’21 (40.00) (47.90) 680.20 (37.60)
554.70
’20 (18.31) (23.23) (23.79) (30.77)
(96.10)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.90) 2.58 — —
—
’25 1.14 (0.84) (0.48) (1.10)
(1.14)
’24 (0.97) (0.49) (0.68) (0.63)
(2.77)
’23 (1.54) (1.25) (1.18) (2.53)
(6.62)
’22 (1.20) (1.32) (1.24) (1.56)
(5.31)
’21 (0.84) (1.03) (0.94) (1.00)
(3.82)
’20 (0.56) (0.65) (0.79) (0.99)
(3.02)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.54 13.57 17.37 5.90 — — —
Low Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 82.86 42.84 53.08 21.00 — — —
High Price
— ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 415 445 430 246 — — —
Employees
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.32 0.18 0.61 1.07 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 131.40 78.50 263.40 262.60 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (251.00) (363.90) (198.30) (80.50) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (191.02%) (463.57%) (75.28%) (30.65%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (282.50) (367.30) (198.90) (80.80) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.70 (8.60) (10.60) (3.30) — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.47 1.41 3.66 3.70 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.31) (6.62) (2.77) (1.14) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.14) (6.27) (3.61) (3.86) ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.13) (0.05) (0.02) (0.03) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.27) (6.32) (3.63) (3.89) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.62 11.89 7.81 6.12 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 53.20 55.50 71.90 70.90 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.51 32.30 5.23 3.20 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.14 3.84 2.45 1.94 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.31 16.20 1.29 0.60 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.02) (3.63) (1.31) (0.57) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (273.50) (347.80) (259.30) (273.80) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.80) (2.90) (1.70) (1.90) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (280.30) (350.70) (261.00) (275.70) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 945.10 1,023.10 837.50 558.20 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.00 0.80 0.60 0.40 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,207.80) (1,265.70) (1,038.80) (685.00) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 564.90 660.00 561.70 433.90 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.82%) (28.55%) (16.60%) (8.93%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.96%) (59.97%) (32.56%) (16.23%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Arvinas, Inc. (ARVN), a clinical-stage biotech leader in PROTAC protein degradation therapies for oncology and neuroscience, finds itself at a pivotal juncture reminiscent of early 2000s biotech inflection points amid today’s high-rate environment. Key milestones include its 2018 IPO and the 2021 Pfizer partnership advancing vepdegestrant (ARV-471) into Phase 3 trials, driving explosive revenue growth from $6.7 million in 2016 to $263.4 million in 2024—a 235% surge fueled by milestone payments. Yet, this lumpy model exposes ARVN to binary risks, with projections showing a mere 10% rise in 2025 before a stark 67% drop in 2026, echoing peers’ post-milestone cliffs.

Financials reflect maturing operations with narrowing losses—from $367 million in 2023 to a projected $49 million in 2025—and robust net cash exceeding $1 billion, yielding a compelling 5x price-to-sales ratio versus frothier historical peaks. Stock performance has stabilized post-80% drawdown from 2021 highs, decoupling somewhat from 2024’s revenue boom amid sector funding droughts, while tepid insider selling and moderate analyst targets (24% mean upside) signal cautious optimism tied to trial catalysts.

Looking ahead, vepdegestrant data readouts in mid-2025 could unlock blockbuster potential and M&A appeal, buoyed by anticipated Fed cuts reviving biotech deals—much like low-rate eras catalyzed past winners. However, execution risks in a 40% Phase 3 failure-prone field demand vigilance, positioning ARVN as an asymmetric bet in a rate-sensitive sector.

Read full commentary →

Arvinas, Inc. (ARVN) Latest News

News by impact score

Fine-tune

9 Sep

5 , 2:22 AM
Arvinas secures FDA approval for its protein degrader, marking the first such regulatory nod and establishing a new milestone in targeted protein degradation therapies. FDA approval of first protein degrader therapy fundamentally strengthens Arvinas pipeline and long-term market position.

3 Sep

3 , 11:50 AM
KT-621 may represent a turning point for Kymera Therapeutics in targeted protein degradation, with potential competitive effects on Arvinas in the PROTAC space. News on Kymera's KT-621 could moderately affect Arvinas market positioning and sentiment but is unlikely to fundamentally shift its trajectory.

11 Aug

3 transcript www.fool.com, 2:05 PM
Arvinas reported Q2 2026 financial results and operational updates during its earnings call, covering pipeline progress, revenue figures, and future guidance for the company's protein degradation platform. Quarterly earnings provide updates on finances and pipeline that can shift near-term sentiment but rarely alter long-term trajectory alone.

4 Aug

3 transcript app.moby.co, 5:41 PM
Arvinas reported Q2 2026 financial results and pipeline progress during its earnings call, including updates on PROTAC programs, cash position, and upcoming clinical milestones. Quarterly earnings updates deliver operational and financial details that moderately influence near-term sentiment without altering long-term company trajectory.

3 transcript www.marketbeat.com, 10:04 AM
Arvinas Q2 earnings call highlighted quarterly financial results, pipeline updates on PROTAC degraders including ARV-471, and outlook on clinical milestones and partnerships. Quarterly earnings and pipeline updates provide financial and development details that moderately influence near-term sentiment without altering long-term trajectory.

3 , 8:50 AM
Arvinas, Inc. (ARVN) exceeded Q2 earnings and revenue estimates. Earnings and revenue beats typically produce short-term positive effects on stock price and sentiment without fundamentally shifting long-term trajectory.

16 Jun

3 , 4:01 PM
Rigel closes licensing agreement for VEPPANU™ (vepdegestrant). Licensing deal closure for vepdegestrant creates moderate partnership revenue and validation potential for Arvinas.

5 Jun

4 www.marketbeat.com, 12:10 PM
Arvinas secures first PROTAC approval, sharpens pipeline focus, and prepares for key trial data readout. First PROTAC approval validates core technology and drives major pipeline and market shifts.

4 Jun

3 GlobeNewswire, 8:00 AM
Arvinas joins The Michael J. Fox Foundation’s LITE and PPMI Programs to develop new LRRK2-targeted therapies for Parkinson’s Disease. Partnership adds early-stage Parkinson’s pipeline expansion for Arvinas without immediate revenue or approved product impact.

16 May

3 Simply Wall St., 9:40 AM
Analysts upgraded forecasts for Arvinas Inc. (NASDAQ:ARVN), reflecting higher expected revenue and earnings that support a bullish view on the company's growth trajectory and market positioning. Analyst forecast upgrades can lift near-term ARVN stock sentiment and valuation but rarely shift long-term fundamentals or competitive dynamics.

15 May

4 Benzinga, 4:31 PM
Rigel Pharmaceuticals signed a deal with Arvinas and Pfizer to advance a breast cancer drug. Partnership with Pfizer and Rigel expands Arvinas breast cancer pipeline and strengthens strategic positioning.

14 May

4 Simply Wall St., 8:48 AM
Arvinas, Inc. (NASDAQ:ARVN) beat analyst earnings forecasts, prompting analysts to raise their price targets amid optimism for future performance. Earnings beat and analyst upgrades signal strong momentum for ARVN's financial trajectory and investor sentiment.

4 Simply Wall St., 2:13 AM
Rigel Pharmaceuticals (RIGL) shares surged 20.5% after securing global rights to VEPPANU in a deal with Pfizer and Arvinas, prompting analysis of whether this strengthens Rigel's bull case. Arvinas gains from licensing global rights to VEPPANU to Rigel via Pfizer, marking a major strategic partnership with potential for significant upfront payments, milestones, and royalties.

13 May

4 Benzinga, 1:54 PM
Analysts raised price targets and earnings forecasts for Arvinas (ARVN) after strong Q1 results, signaling optimism about the biotech firm's pipeline and financial outlook. Analyst upgrades after Q1 results boost investor sentiment and could drive significant near-term stock gains for ARVN.

4 Simply Wall St., 4:17 AM
Pfizer transfers VEPPANU rights to Rigel Pharmaceuticals amid persistent valuation gaps with Arvinas, Inc. (ARVN). Pfizer offloading VEPPANU rights to Rigel exposes Arvinas' pipeline asset to devaluation risks, threatening partnerships and investor confidence.

3 transcript app.moby.co, 8:30 AM
Arvinas reported Q1 2026 financial results and pipeline progress during its earnings call, highlighting clinical updates for protein degradation programs and cash position guidance. Quarterly earnings call delivers operational and financial details that can shift near-term sentiment without altering long-term strategy.

12 May

4 GuruFocus.com, 3:01 PM
Arvinas Inc (ARVN) Q1 2026 earnings call highlights strategic advances amid revenue decline. Strategic advances in Q1 2026 earnings offset revenue decline, likely shifting investor sentiment and company trajectory.

4 www.marketbeat.com, 10:08 AM
Arvinas (ARVN) Q1 earnings call highlights financial results, clinical pipeline updates on PROTAC degraders, cash position, and upcoming milestones. Q1 earnings highlights detail pipeline advancements and financials poised to significantly sway ARVN investor sentiment and stock trajectory.

4 www.biopharmadive.com, 8:05 AM
Arvinas and Pfizer have secured a new partner for their Protac-based breast cancer drug. New partnership for Protac breast cancer drug enables accelerated development, potential milestone payments, and expanded market reach for Arvinas.

4 PR Newswire, 7:00 AM
Rigel Pharmaceuticals enters exclusive global licensing agreement with Arvinas for VEPPANU™ (vepdegestrant), an oral PROTAC estrogen receptor degrader, targeting second-line and later ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. Exclusive global licensing deal for Arvinas' key PROTAC candidate in lucrative breast cancer market delivers upfront payments, milestones, royalties, and pipeline validation.

4 , 7:00 AM
Arvinas and Pfizer have entered a transaction with Rigel Pharmaceuticals to obtain exclusive global rights to VEPPANU (vepdegestrant), advancing their oncology pipeline. Securing exclusive global rights to VEPPANU via partnership with Pfizer and Rigel represents a major strategic expansion of Arvinas' clinical assets and potential revenue streams.

3 GlobeNewswire, 7:05 AM
Arvinas, Inc. (ARVN) reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates moderately influence ARVN's financial performance and investor sentiment.

6 May

4 GlobeNewswire, 9:35 AM
Arvinas (ARVN) Q2 2026 catalyst outlook highlights trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. Pipeline catalysts like trial readouts and PDUFA dates in Q2 2026 could significantly boost ARVN's valuation and investor sentiment.

4 May

5 www.pharmavoice.com, 5:06 AM
Arvinas, Inc. (ARVN) secures landmark regulatory approval for its protein degrader therapy, accelerating momentum in the protein degradation field. Landmark approval fundamentally redefines Arvinas' competitive position and long-term prospects as a leader in protein degraders.

4 Business Wire, 8:05 AM
Guardant Health received FDA approval for Guardant360 CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) in ER+/HER2- advanced breast cancer patients with ESR1 mutations. FDA approval of companion diagnostic for vepdegestrant advances Arvinas' commercialization path and bolsters investor sentiment in targeted breast cancer therapy.

3 May

4 Simply Wall St., 3:10 AM
Arvinas (ARVN) investment narrative shifts positively with key milestones in Vepdeg, a PROTAC degrader for breast cancer partnered with Pfizer, and ARV-102, a preclinical candidate targeting neurodegeneration, signaling pipeline progress and potential value inflection. Vepdeg and ARV-102 milestones mark major clinical and strategic advancements in ARVN's protein degradation pipeline, poised to significantly enhance future prospects and investor sentiment.

1 May

5 GlobeNewswire, 12:43 PM
Arvinas, Inc. (ARVN) announces FDA approval of VEPPANU (vepdegestrant) for treating ESR1m, ER+/HER2- advanced breast cancer. FDA approval of a novel therapy for advanced breast cancer fundamentally transforms Arvinas' competitive position and long-term prospects.

4 www.biopharmadive.com, 12:01 PM
FDA clears Arvinas’ Protac breast cancer drug, marking a key advancement for the company's protein degradation platform in oncology. FDA clearance of a Protac-based breast cancer drug advances Arvinas' clinical pipeline and enhances market prospects significantly.

4 Apr

4 Simply Wall St., 10:11 PM
Arvinas (ARVN) narrative evolves ahead of key 2026 neurology catalysts, highlighting advancing pipeline developments and potential breakthroughs in protein degradation therapies. 2026 neurology catalysts signal major pipeline advancements poised to reshape ARVN's competitive position and market trajectory.

18 Mar

4 GlobeNewswire, 7:00 AM
Arvinas announced positive Phase 1 data for ARV-102, achieving greater than 50% LRRK2 degradation in the cerebrospinal fluid of Parkinson’s disease patients after 28 days of treatment. Positive Phase 1 data demonstrating >50% target degradation in CSF validates ARV-102's mechanism in Parkinson’s, potentially boosting Arvinas' pipeline expansion into neuroscience and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us